Latest News Release

Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin

Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial

Oncolytics Biotech Inc.’s Research Collaborators Present REOLYSIN® Phase I UK Systemic Administration Clinical Trial Results

Oncolytics Biotech Inc. Reports REOLYSIN® and Chemotherapeutic Agents are Synergistic Against NSCL Cancer Cell Lines

Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Research at 18th EORTC-NCI-AACR Symposium

Oncolytics Biotech Inc. Announces 2006 Third Quarter Results

Oncolytics Biotech Inc. to Present at Rodman & Renshaw 8th Annual Healthcare Conference

Oncolytics Biotech Inc. to Present at PIPEs Conference


Year

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

Follow us on Twitter